Overview

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Status:
Completed

Trial end date:
2016-06-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an isocitrate dehydrogenase-2 (IDH2) mutation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Agios Pharmaceuticals, Inc.
Celgene

Collaborator:

Celgene Corporation